AD/PD 2021 Archives - VJNeurology

Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

The 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021, was held virtually, on March 9-14, 2021.

The conference attracted international medical and scientific professionals worldwide, who discussed mechanisms of disease, prevention and treatment of Alzheimer’s disease, Parkinson’s disease and other related neurodegenerative diseases.

Explore the latest updates in the field by viewing our interviews with key experts!

Latest videos from AD/PD 2021

View all

Donanemab in early-stage AD: a highlight from AD/PD

Sangram Sisodia • 16 Mar 2021

AD/PD 2021 highlights: immunotherapies, 3D cell models and copathologies

Tiago Outeiro • 16 Mar 2021

Improving Phase II trials in AD drug development

Jeffrey Cummings • 15 Mar 2021

PASADENA trial: prasinezumab in early Parkinson’s disease

Gennaro Pagano • 10 Mar 2021

Alzheimer's disease

View all

Better diagnostic methods and therapies for Alzheimer’s disease

Colin L. Masters • 11 Mar 2021

MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease

Marwan Sabbagh • 8 Mar 2021

The influence of TREM2 variant expression in AD pathogenesis

Christina Toomey • 10 Mar 2021

Hormonal, neuroimmune, and systemic vascular influences in Alzheimer’s disease

Costantino Iadecola • 11 Mar 2021

Parkinson's disease

View all

Chronic gut inflammation confers a sex-dependent PD vulnerability

Malú Tansey • 8 Mar 2021

Opportunities for precision medicine in Parkinson’s disease: DJ-1 mutations

Rejko Krüger • 9 Mar 2021

Late-onset depression as a risk factor for prodromal PD

Anette Schrag • 15 Mar 2021

Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease

Gennaro Pagano • 10 Mar 2021